Although the mitotic arrest effect of AXL1717 may contribute to the hematological AEs observed in this and the previous study by Ekman et al. [9], this mechanism of action of AXL1717 in combination with IGF-1R inhibition may be favorable, or even crucial, for the anti-tumor efficacy of the drug. The gene discussed is IGF1R; the disease is neoplasm.